Popular Chips Recalled Over ‘Life-Threatening' Reaction Risk, Per FDA
Certain bags of Tostitos chips are being recalled over concerns of 'life-threatening' allergic reactions.
The U.S. Food and Drug Administration (FDA) shared information on the exact product affected by the recall.
Here is how to tell if your chips are included in the recall and what to do.
The latest food recall affects snack cabinets across several states. The U.S. Food and Drug Administration (FDA) announced a recall last week for Frito-Lay's popular Tostitos tortilla chips. While the recall has yet to be categorized, the FDA describes the case as potentially 'serious or life-threatening' for certain individuals.
Approximately 1,000 bags of Tostitos Cantina Traditional Yellow Corn Tortilla Chips are affected by the recall as they may contain milk, an undeclared allergen. The affected bags may include a variety of nacho cheese tortilla chips, which are made with milk.
According to the FDA, 'those with an allergy or severe sensitivity to milk' should not consume the recalled product. However, in a media statement from Frito-Lay, the manufacturer confirmed that the product 'is safe to consume' if the consumer does not have a dairy allergy or sensitivity. 'No allergic reactions related to this matter have been reported to date,' the FDA confirmed, adding that no other Tostitos products are affected by the recall.
The specific products included in the recall are 13 oz. bags of Tostitos Cantina Traditional Yellow Corn Tortilla Chips distributed in 13 states: Alabama, Florida, Georgia, Illinois, Indiana, Kentucky, Mississippi, North Carolina, Ohio, South Carolina, Tennessee, Virginia, and West Virginia. Bags were available for purchase as early as March 7, 2025, from grocery stores, convenience stores, drug stores, and e-commerce distributors.
Impacted products will have a UPC of 28400 or 52848, a 'guaranteed fresh' date of 20 May 2025, and have one of the following manufacturing codes (where 'XX' is any number from 30 up to 55):
471106504; 18 13:XX
471106505; 85 13:XX
471106506; 85 13:XX
471106507; 85 13:XX
Anyone in possession of the product who also has an allergy or sensitivity to milk should not consume it and discard it immediately, per the FDA.
If you believe you have impacted bags, visit the Frito-Lay Contact Us page here or call 1-800-352-4477 (9 a.m.–4:30 p.m. CST, Monday-Friday) for more information.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
14 minutes ago
- CBS News
Acid spill at Cold Springs Pilgrim's plant sends 26 to hospital, police say
Minneapolis City Council calls for investigation into federal raid, and more headlines Minneapolis City Council calls for investigation into federal raid, and more headlines Minneapolis City Council calls for investigation into federal raid, and more headlines More than two dozen people were hospitalized after an acid spill at a chicken facility in central Minnesota Friday morning, police said. A peracetic acid spill occurred at the Pilgrim's facility on the 800 block of Sauk River Road in Cold Spring around 8:15 a.m., according to the city's police department. The spill was contained and the facility was evacuated. Twenty-six people were taken to a nearby hospital for evaluation. The U.S. Food and Drug Administration said peracetic acid is often used as a cleaning agent. In poultry facilities, it is often used "to reduce bacterial contamination and foot spoilage," the FDA said. The acid's concentrated form can cause "irreversible damage to skin and eyes," the FDA said, while the diluted forms can cause eye, nose, throat and respiratory irritation. The Pilgrim's facility recently underwent a $75 million expansion. Cold Spring is about 80 miles northwest of Minneapolis. This story will be updated.
Yahoo
18 minutes ago
- Yahoo
The 9 best deodorants and antiperspirants for men in 2025, according to testers and dermatologists
If you haven't realized by now, men's deodorant isn't one size fits all. You have the option between deodorant and antiperspirant, then the choice of solids, gels, sprays or wipes, plus 24-, 48- or 72-hour protection. It gets kind of overwhelming to think about, but there's a purpose for every deodorant option out there. To help you break down the madness so you can choose the best deodorant and/or antiperspirant for you, we turned to a panel of experts, including dermatologists and in-house testers. For starters, we asked about the difference between a deodorant and an antiperspirant, and why you might want both in one product. "Deodorants mask the odor, while antiperspirants prevent you from sweating," said Dr. Monika Kaniszewska, a board-certified dermatologist based in Chicago. So, in order to stop stink and sweat, you'll want a combination of both. With feedback from our experts, we compared dozens of products, from extra-strength sweat-stopping antiperspirants to gentle, all-natural, aluminum-free deodorants, to find the best of the best. Whether you're looking for an all-natural deodorant for men, designed to stop the stink without harsh chemicals, or the best antiperspirant for men to block sweat completely, this list has you covered. Best deodorant for men overall for 2025 Other top deodorants for men we recommend for 2025 What to consider when buying the best deodorant for men How we chose the best deodorant for men FAQs Meet our experts Update, June 6, 2025: We checked all product prices, availability and specs. Our number one pick for the best men's deodorant remains unchanged. (back to top) (back to top) While some people use the terms "antiperspirant" and "deodorant" interchangeably, these are two different things. According to Dr. Camila Antia, a Houston-based dermatologist, "Antiperspirants control sweat by blocking sweat glands, usually with aluminum compounds. Deodorants, on the other hand, primarily mask odor and may contain antimicrobial agents. Some products are combination antiperspirant deodorants, providing both functions." The difference means that if excessive sweating is your main concern, antiperspirants are better suited for you than a standard deodorant. You can tell whether a product is an antiperspirant by looking for the term "antiperspirant" on the label. Furthermore, in the United States, antiperspirants are regulated by the FDA as an over-the-counter drug and have drug information panels on their labels. Many deodorants claim to be all-natural, but if you're shopping in the United States, this term means little in terms of cosmetics. However, many deodorants advertised as "natural" are free from parabens, which are preservatives often found in many cosmetics. Some research has suggested that parabens can disrupt human hormone production, but the Centers for Disease Control and Prevention says "health effects from environmental exposure to low levels of parabens are unknown." Aluminum-based antiperspirants: Various aluminum compounds are used in antiperspirants because they work to reduce the release of sweat by physically blocking it from exiting the sweat glands, chemically inhibiting sweat release, or a combination of the two. Sodium bicarbonate (baking soda): Baking soda acts as a deodorizer, partially by killing the bacteria that cause body odor. While baking soda is nontoxic, it can cause skin irritation. Avoid it if you have sensitive skin. Fragrances: In the United States, companies are not required to list ingredients added to products to create scents, but fragrances can cause allergic reactions. Since there's no way to identify which chemical caused the reaction, those who've had allergic reactions to fragrances should choose unscented deodorants. Solid: Solid deodorants are just that — solid rather than liquid or gel-like. Solids are often bright white, which can lead to stains on darker clothing. Invisible solid: Invisible solids are identical to other solids except they go on clear instead of white. Roll-on deodorant: Roll-on deodorants are liquid and often have a smooth, gel-like consistency. You apply these deodorants by rubbing a roller ball at the end of a tube against your skin. The biggest downside is that they can leave you feeling a little wet and sticky for a few moments until they're completely absorbed by your skin. Spray: Spray, or aerosol, deodorants are applied by spraying under your armpits, like you would a spray-on sunscreen. Gel: Some deodorants come in gel form but are applied like a solid deodorant rather than a roll-on. These deodorants don't leave stains, unlike most solids. However, they can take a while to dry. Wipe: Wipes can be an easy way to reapply deodorant throughout the day if you need to remove some sweat in the process. Most don't contain antiperspirant and tend to be on the expensive side. Many deodorants and antiperspirants are labeled "extra-strength." This usually means that they have more of whatever active ingredient (typically aluminum) included to keep you dry and smelling fresh. Figuring out whether you need an extra-strength product is a matter of trial and error. Different deodorants and antiperspirants claim to last different amounts of time. Most last for a minimum of a day, while others claim to last up to three or four days. While these results vary, you might want to choose a longer-lasting product if you forget to reapply or don't shower every day. Since deodorants and antiperspirants need to be reapplied at least once every couple of days, choosing one that you can afford to purchase on a regular basis is important. Deodorants advertised as "all-natural" and ones from luxury brands tend to be more expensive, yet may or may not contain sweat- or smell-blocking ingredients. More popular brands can sometimes be bought in bulk online, which can drive down the cost per stick. When evaluating the price of a product, make sure to check not only how many sticks of deodorant are included, but also how many ounces of product are in each stick, since each product can vary in size. (back to top) We evaluated dozens of deodorant and antiperspirant products and spoke to board-certified dermatologists, in addition to reviewing the scientific literature. We chose products that received positive reviews online that provided a breadth of features, depending on the category. We rated each product based on variables such as ingredients, cost, longevity, scents and what the product stated it was designed to do. (back to top) Yes, says Antia. "Generally, antiperspirant deodorants are considered safe for most people. They work by reducing sweat production and often contain aluminum compounds. Some individuals may be sensitive to certain ingredients, so it's advisable to check for any allergic reactions." Nope. "The strength of deodorants is not necessarily determined by gender," Antia says. "Some products may be marketed with specific scents or packaging for men or women, but the effectiveness is more related to the formulation." So if you like that lilac-scented deodorant you sniffed at the drugstore, go for it. Although the conventional wisdom is that you should apply deodorant after your morning shower, that's not when it's most effective to do so. Antia says that "it's best to apply antiperspirant to clean, dry skin at night. Sweat gland activity decreases during sleep. Nighttime application allows the active ingredients, such as aluminum-based compounds, more time to penetrate and block sweat ducts. It also allows the product to dry thoroughly and decreases the chance of irritation." That depends. Different products claim to last a variety of times: anywhere from one to three or four days. Antia says that while these claims can be true, your results depend far more on your lifestyle and biology. "Whether a deodorant can last for 48 hours depends on factors such as individual sweat rates, activity levels and product composition." No and no. Dr. Natalie Hone, a dermatologist in Houston, says aluminum is needed for a deodorant to have antiperspirant properties. "Aluminum-free deodorants work by neutralizing odor but do not reduce sweat like antiperspirants." So while you may want to avoid aluminum if you're allergic, don't worry about it giving you cancer. While it's been suggested that aluminum can cause various ailments and disorders, most notably Alzheimer's disease and breast cancer, there is no evidence that antiperspirants cause any health concerns, including no link between antiperspirant use and breast cancer. "If excessive sweating or persistent odor becomes a concern, it's advisable to consult with your dermatologist," Hone said. "They can help determine if there's an underlying medical issue or recommend suitable solutions." If over-the-counter solutions aren't working for you, there is still hope, she said. "There are several treatment options for patients with severe sweating, also known as hyperhidrosis. Options include topical towelettes, oral medications and even neurotoxin injections to the area." (back to top) Camila Antia, MD, board-certified dermatologist Natalie Hone, MD, board-certified dermatologist Amy Forman Taub, MD, FAAD, board-certified dermatologist; founder, Advanced Dermatology and Monika Kaniszewska, MD, FAAD, board-certified dermatologist (back to top) Our health content is for informational purposes only and is not intended as professional medical advice. Consult a medical professional on questions about your health.
Yahoo
2 hours ago
- Yahoo
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology VSTM shares rallied 22.2% in a month, primarily driven by the FDA approval of the company's novel combination regimen of avutometinib plus defactinib in early May for treating KRAS mutant recurrent low-grade serous ovarian cancer (LGSOC), a rare and distinct type of ovarian cancer. The FDA's decision came well in advance of the originally expected date of June 30, 2025. The approval was granted under the FDA's accelerated approval pathway and is commercialized in the U.S. market as an oral combination co-pack with the two prescription products, known as 'Avmapki Fakzynja Co-Pack.' Following the FDA approval, Avmapki Fakzynja Co-Pack is the first and only FDA-approved treatment for the LGSOC indication. Per Verastem Oncology, the combo offers a much-needed treatment option for patients and sets a new standard of care for women with recurrent LGSOC with a KRAS mutation. Full approval of the product for this use depends on the detailed evidence of clinical benefit in the follow-up phase III RAMP 301 confirmatory study, which will evaluate the combination in women with and without a KRAS mutation. Year to date, Verastem Oncology stock has surged 64.8% against the industry's 5.8% decline. Image Source: Zacks Investment Research Please note that the FDA's decision was based on the results from VSTM's phase II RAMP 201 study, which evaluated the combination of Avmapki and Fakzynja in adult patients with measurable KRAS-mutated recurrent LGSOC. Per the data readout, a 44% overall response rate was observed in patients treated with the combo therapy, with an acceptable safety profile. Additionally, the median duration of response ranged from 3.3 to 31.1 months in the KRAS mutant population. The Avmapki/Fakzynja combo enjoys the FDA's Breakthrough Therapy designation for the treatment of patients with recurrent LGSOC after one or more prior lines of therapy, including platinum-based chemotherapy, in the United States. Avutometinib alone or in combination with defactinib also enjoys the FDA's Orphan Drug designation for the same indication. Verastem Oncology is also looking to expand the label of its approved avutometinib/defactinib combo therapy beyond LGSOC. Last week, VSTM reported positive updated safety and efficacy results from the phase I/II RAMP 205 study evaluating avutometinib plus defactinib in combination with chemotherapy (gemcitabine and Nab-paclitaxel) for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) patients. This has also likely contributed to the stock price rally in the past month. The RAMP 205 study is evaluating 60 patients in five cohorts (12 per cohort) who are receiving one of five dose regimens of avutometinib/defactinib combo with chemotherapy for frontline metastatic PDAC. As of April 25, 2025, patients in the dose level 1 cohort achieved an overall response rate of 83% (eight confirmed and two unconfirmed who remain on treatment). Based on this encouraging outcome, Verastem Oncology selected dose level 1 as the recommended phase II dose. Additionally, it was found that the dose level 1 showed the best response, and overall, 92% of patients across all dose levels achieved tumor shrinkage. The safety profile of the avutometinib/defactinib combo was acceptable across all the treatment cohorts and no new safety signals were identified. Verastem Oncology is currently gearing up to initiate a registrational phase III front-line metastatic PDAC study in 2026. Apart from these indications, the company is simultaneously evaluating avutometinib and defactinib in combination with a KRAS G12C inhibitor, sotorasib, for treating non-small cell lung cancer in a separate mid-stage study. Verastem, Inc. price-consensus-chart | Verastem, Inc. Quote Verastem Oncology currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Bayer BAYRY, Lexicon Pharmaceuticals LXRX and Amarin AMRN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Bayer's earnings per share have increased from $1.19 to $1.25 for 2025. During the same time, earnings per share have increased from $1.28 to $1.31 for 2026. Year to date, shares of Bayer have gained 45.3%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. In the past 60 days, estimates for Lexicon's loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 6.6%. LXRX's earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%. In the past 60 days, estimates for Amarin's loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 17.1%. AMRN's earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Lexicon Pharmaceuticals, Inc. (LXRX) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Verastem, Inc. (VSTM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
